Background-Previous work on contrast-induced acute kidney injury (CI-AKI) has identified contrast volume as a risk factor and suggested that there is a maximum allowable contrast dose (MACD) above which the risk of CI-AKI is markedly increased. We hypothesized that there is a relationship between contrast volume and CI-AKI and that there might be reason to track incremental contrast volumes above and below the MACD limit. Methods and Results-Consecutive patients undergoing percutaneous coronary intervention (PCI) were prospectively enrolled from 2000 to 2008 (nϭ10 065). Patients on dialysis before PCI were excluded (nϭ155). MACD was defined as (5 mLϫbody weight [kg])/baseline serum creatinine [mg/dL]) and divided into categories in which 1.0 reflects the MACD limit: ՅMACD ratios (Ͻ0.5, 0.5 to 0.75, and 0.75 to 1.0) and ϾMACD (1.0 to 1.5, 1.5 to 2.0, and Ͼ2.0). CI-AKI was defined as a Ն0.3 (mg/dL) or Ն50% increase in serum creatinine from baseline or new dialysis. Multivariable regression was conducted to evaluate the effect of exceeding the MACD on CI-AKI. 
M ore than 1.2 million cardiac catheterizations are conducted in the United States each year, 1 precipitating approximately 120 000 new cases of contrast-induced acute kidney injury (CI-AKI). CI-AKI results from acute tubular necrosis from nephrotoxic iodinated contrast dye administered intraarterially during the procedure and from other homeostatic factors 2, 3 and is a serious complication resulting in increased short-and long-term mortality and morbidity. 4 
Clinical Perspective on p 350
Recently, there has been more focus on preventing CI-AKI with hydration and pharmaceutical interventions than on the older concept of a maximal acceptable contrast dose (MACD). 5, 6 Although hydration and pharmaceutical interventions to protect against kidney injury are important, the additional issue of volume of contrast and risk of kidney injury has been lacking. Therefore, we sought to identify the rate of CI-AKI and other clinical outcomes among patients that did and did not exceed the MACD of iodinated contrast. The purpose of this investigation is to identify the relationship between the volume of current contrast agents and patient body weight and baseline renal function and determine whether tailoring the dose of contrast could place patients at higher or lower risk of CI-AKI during a percutaneous coronary intervention (PCI).
Methods
The Dartmouth Dynamic Registry is a large prospective, clinical, consecutive patient registry of patients undergoing diagnostic or interventional cardiovascular catheterization procedures at the Dartmouth-Hitchcock Medical Center. 4 In the present study, consecutive patients undergoing PCI were prospectively enrolled in the Dartmouth Dynamic Registry from 2000 to 2008 (nϭ10 065). Patients with preexisting dialysis-dependent renal failure were excluded (nϭ155). The registry was approved by the Dartmouth Center for the Protection of Human Subjects. The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Data Collection and Definitions
Patient and disease characteristics, including history of comorbidities, procedural characteristics, and clinical outcomes, are prospectively collected in the Dartmouth Dynamic Registry and have been previously described. 4 The prospective cohort did not capture complete preprocedure and postprocedure prophylaxis for NaCl, NaHCO 3 , N-acetylcysteine. Rehman et al 7 recently demonstrated that N-acetylcysteine does not falsely lower serum creatinine. The last preprocedure serum creatinine values and a routine postoperative serum creatinine were obtained on all patients within 24 hours of the procedure before discharge. Subsequent serum creatinines were available only to the extent that they were thought to be clinically relevant by the patient's physician and obtained by linking to the in-hospital laboratory system. The last preprocedure and peak postprocedure creatinine values were used to define CI-AKI. CI-AKI was defined as a Ն0.3 (mg/dL) or Ն50% increase in peak serum creatinine from baseline or new onset of dialysis-dependent renal failure according to the AKIN criteria during the index catheterization admission. 8 MACD was defined as (5 mLϫbody weight [kg])/baseline serum creatinine [mg/dL]) as defined by Cigarroa et al. 6 Ratios of contrast volume:MACD were calculated. Ratios Յ1 represent contrast volumes that did not exceed the MACD. Ratios Ͼ1 represent contrast volumes administered that exceeded the MACD threshold.
Statistical Methods
Baseline patient disease and characteristics, procedural characteristics, and clinical outcomes were compared between patients exceeding versus not exceeding the MACD exposure by 2 tests and Student t tests. To help control for confounding when comparing the incidence of CI-AKI between these groups, we developed a multivariate logistic regression model for this end point. Univariate logistic regression was used to identify risk factors for CI-AKI. Those with a probability value Ͻ0.10 were incorporated into a multivariate logistic regression made parsimonious by comparing nested models using the likelihood ratio 2 test. 9 Variables in the final model included age, sex, body surface area, diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, priority of PCI, number of stents inserted, and baseline estimated glomerular filtration rate using MDRD equation (eGFR). Adjusted rates of CI-AKI were then calculated and compared using direct standardization.
To assess the robustness of our findings, we used propensity score matching as an alternative method to control for differences in the cohorts of patients exceeding versus not exceeding the MACD. In this approach, logistic regression was used to calculate for each patient the probability they would exceed the MACD based on the previously developed Mehran risk score (congestive heart failure, hypotension, intraaortic balloon pump, age Ͼ75 years, anemia, diabetes mellitus, and eGFR). 10 Patients were then stratified into 13 blocks on the basis of their predicted probability of exceeding the MACD using the "pscore" algorithm in Stata, such that patients within a given block had similar predicted probabilities. Within each block, the algorithm checked to insure a reasonable balance of patients exceeding versus not exceeding the MACD, the exposure of interest.
Because contrast volume was an aspect of our exposure (MACD), we did not include contrast volume as part of our propensity matching. 10 We then calculated the average treatment effect associated with exceeding versus not exceeding the MACD using conditional logistic.
In a subgroup analysis, we evaluated additional categories above and below the threshold (1.0) according to the ratio of contrast volume:MACD; the categories were as follows: Ͻ0.5, 0.5 to 0.75, 0.75 to 1.0, 1.0 to 1.5, 1.5 to 2.0, and Ͼ2.0. These categories were plotted with crude and direct adjusted rates of CI-AKI as described above. Multivariable logistic regression was used to test for differences across categories above (Ͻ1.0, 1.0 to 1.5, 1.5 to 2.0, and Ͼ2.0) and below (Ͻ0.5, 0.5 to 0.75 and 0.75 to 1.0). All analyses were conducted using Stata 9.0 statistical software (College Station, Tex).
Results
Twenty percent of patients undergoing PCI procedures exceeded the MACD (Table 1) . Patients differed with regard to baseline ( Table 1 ) and procedural characteristics ( Table 2) . Patients exceeding the MACD threshold were more likely to be in shock, have 2-or 3-vessel disease and left main stenosis, and more stents ( Table 2) .
Patients receiving contrast volumes in excess of the MACD were more likely to have CI-AKI, new onset of dialysisdependent renal failure, cardiac events, bleeding complications, receive transfusion, and a longer length of stay after PCI and were more likely to die during the PCI admission (Tables 3). Adjusted and propensity-matched odds ratios for the clinical outcomes are reported in Table 4 . The propensity-matched results-using the Mehran risk score without contrast volume for matching-reported consistent findings with the adjusted modeling for CI-AKI, dialysis, and in-hospital mortality.
Ratios of contrast volumes that exceeded or did not exceed the MACD threshold are plotted in the Figure. Risk-adjusted CI- Radiocontrast dye has been postulated to increase vasoconstriction and cause increases in the extracellular calcium influx or decreases in renal blood flow and the loss of nitric oxide production, leading to a loss of the outer medullary autoregulation and acute tubular necrosis. 2, 3, 11 Romano et al 12 have demonstrated that low and isoosmolar contrast media causes renal cell apoptosis through DNA fragmentation in the renal medulla from medullary hypoxia.
Taliercio et al 13 showed that repeated exposure to contrast within 72 hours is associated with an increased risk of CI-AKI. Cigarroa et al 6 followed by developing the MACD equation currently used today to determine the threshold for safe contrast exposure customized to each patient. It is important to note that Cigarroa's equation of MACD was developed during the time that high osmolar contrast media was used; this equation has not been validated in the low and isoosmolar contrast media use of today. The MACD, or contrast material limit, is calculated by 5 (mL) of contrast per kilogram of body weight/baseline serum creatinine (mg/dL). Cigarroa et al 6 determined that a maximum of 300 mL of contrast should be used regardless of the tailored threshold for each patient. In terms of risk for CI-AKI, Cigarroa found that CI-AKI developed in only 2% of patients who had contrast exposure under the calculated threshold, but 38% of patients receiving contrast over the MACD had CI-AKI. 6 Freeman et al 14 showed that exceeding the MACD had a significant 6-fold increased risk of developing nephropathy requiring dialysis. Rihal et al 15 found that contrast dose has been shown to be pernicious over customized thresholds. In PCI patients, each 100 mL of contrast was associated with a 12% increased risk of CI-AKI. Another method proposed by Laskey et al 16 in identifying thresholds of contrast is volume-to-creatinine clearance Adjusted ORs are for age, sex, body surface area, diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, priority, baseline estimated glomerular filtration rates using MDRD equation, and stent count. Propensity is matched for Mehran risk score using conditional logistic regression.
ratio. Laskey proposes that dividing the volume of contrast by the baseline creatinine clearance, whereby volume/creatinine clearance Ն3.7 was significantly associated with an early increase in creatinine, or CI-AKI. 16 Most recently, Marenzi et al 17 confirmed that contrast volume and exceeding the MACD is associated with an increased risk of CI-AKI by 2-fold in patients with ST-elevation myocardial infarction undergoing primary PCI. Our PCI cohort including all patients also found that 20% of patients undergoing PCI exceeded the MACD. We also demonstrated that the relationship between exceeding the MACD threshold and CI-AKI was linear, whereby a 45% increase risk of CI-AKI was associated for each category (1 to 1.5, 1.5 to 2, and Ͼ2) above the threshold. We recommend that MACD should be determined before the procedure and implemented whenever feasible. Exceptions to this rule include complicated long cases, and complete revascularization should be paramount over prevention of CI-AKI; however, exceeding the MACD and increasing the potential threat of CI-AKI should be closely monitored and weighed in every case.
There are several limitations to consider. Although we were able to confirm results from other institutions, we are reporting on a cohort of patients from a single medical center. Additional work is needed to confirm our results from a multicentered registry. All patients received intravenous hydration before their PCI; however, our prospective cohort did not capture prophylaxis data and therefore we were unable to accurately capture true prophylaxis. We reported an increased risk of in-hospital events, including dialysis and mortality; the long-term postdischarge association of mortality and end-stage renal disease should be investigated. We conducted our analysis on a consecutive cohort of PCI patients with complete before and after PCI serum creatinine values. However, the length of stay ranged from 2.2 to 2.8 days on average, and some patients may not have developed CI-AKI before discharge; therefore, our capture of CI-AKI is underrepresenting the true burden of AKI in this population, as has been suggested by Maioli et al 18 Although we conducted a rigorous analysis through multivariable analysis and propensity matching to deal with confounding, there may be residual confounding due to unmeasured covariates. The propensity score matching is not a randomized trial; however, it provides a retrospective method to align similar-risk patients in a cohort analysis. However, on average, patients exceeding the MACD have poorer baseline renal function, more comorbidities, a greater burden of coronary artery disease, and procedures that are associated with a higher dose of contrast. We controlled for these differences with adjustment and propensity matching and still found that when patients exceeded their MACD, it was associated with an increased risk of CI-AKI as well as all other short-term outcomes. It is still possible though not probable that these patients did better with their high-contrast volume procedures than they would have with lower-volume procedures because they had more complete revascularization and with less complete revascularization (lower contrast volume) they would have had a higher mortality rate. However, this does not negate the risk of CI-AKI and the subsequent risk of in-hospital and long-term mortality whereby the risk of mortality and subsequent morbidity for incomplete revascularization compared with developing CI-AKI has yet to be determined in the literature. Although we found differences between patients receiving contrast volumes above and below the MACD caused by differences in baseline renal function and severity of case mix, we emphasize the necessity of using the MACD among highrisk patients to help plan for the procedure through adequate hydration and prophylaxis, minimizing of contrast volume, and consider the risk:benefit ratio of a timeout in the cath laboratory when the MACD threshold is approached. Finally, we are validating a 20-year-old equation to calculate the MACD; although this was developed on the last generation of highosmolality contrast agents, it varies in use in today's cath labs; a modification of this equation may be required, yet in the meantime we have found this to be a useful tool for guiding tailored care for patients.
Recent work by Nyman et al 11, 19 investigates a modernization of the MACD dose to incorporate the role of grams of iodine in the risk modeling for MACD and the risk of CI-AKI. Nyman et al 19 demonstrated that CI-AKI was elevated by more than 6-fold among patients receiving more than a 1:1 ratio of grams of iodine to eGFR. More work must be done to streamline simple calculations in our cath laboratory programs to inform decisionmaking before the case. Our current investigation provides the interventional team with a tool for how much the risk of CI-AKI is increased when the MACD is exceeded. Although alternatives to complex cases with long duration and high dye loads must be considered (staged procedures, medial management, or surgery), the most cost-effective approach to ensure adequate protection against CI-AKI is hydration.
In conclusion, contrast volume does matter and matters most in the patients at highest risk for CI-AKI. Exceeding the MACD for a patient undergoing cardiac catheterization with intervention is associated with an increased risk of CI-AKI by 45% for each 50% in excess of the MACD threshold. Calculating the MACD before interventional cardiac catheterization procedures may be a useful tool for minimizing contrast exposure and aiding in decision making for staging interventional procedures. Additional caution should be used for contrast volumes below the MACD as CI-AKI remains an adverse outcome for patients even when the threshold is not exceeded.
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